These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

521 related articles for article (PubMed ID: 20428822)

  • 1. Prognostic value of MGMT promoter methylation in glioblastoma patients treated with temozolomide-based chemoradiation: a Portuguese multicentre study.
    Costa BM; Caeiro C; Guimarães I; Martinho O; Jaraquemada T; Augusto I; Castro L; Osório L; Linhares P; Honavar M; Resende M; Braga F; Silva A; Pardal F; Amorim J; Nabiço R; Almeida R; Alegria C; Pires M; Pinheiro C; Carvalho E; Lopes JM; Costa P; Damasceno M; Reis RM
    Oncol Rep; 2010 Jun; 23(6):1655-62. PubMed ID: 20428822
    [TBL] [Abstract][Full Text] [Related]  

  • 2. O(6) -methylguanine-DNA methyltransferase (MGMT) promoter methylation and low MGMT-encoded protein expression as prognostic markers in glioblastoma patients treated with biodegradable carmustine wafer implants after initial surgery followed by radiotherapy with concomitant and adjuvant temozolomide.
    Lechapt-Zalcman E; Levallet G; Dugué AE; Vital A; Diebold MD; Menei P; Colin P; Peruzzy P; Emery E; Bernaudin M; Chapon F; Guillamo JS
    Cancer; 2012 Sep; 118(18):4545-54. PubMed ID: 22359215
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide.
    Hegi ME; Diserens AC; Godard S; Dietrich PY; Regli L; Ostermann S; Otten P; Van Melle G; de Tribolet N; Stupp R
    Clin Cancer Res; 2004 Mar; 10(6):1871-4. PubMed ID: 15041700
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of MGMT promoter status in non-resectable glioblastoma after adjuvant therapy.
    Iaccarino C; Orlandi E; Ruggeri F; Nicoli D; Torricelli F; Maggi M; Cerasti D; Pisanello A; Pedrazzi G; Froio E; Crafa P; D'Abbiero N; Michiara M; Ghadirpour R; Servadei F
    Clin Neurol Neurosurg; 2015 May; 132():1-8. PubMed ID: 25723791
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlation between O6-methylguanine-DNA methyltransferase and survival in elderly patients with glioblastoma treated with radiotherapy plus concomitant and adjuvant temozolomide.
    Minniti G; Salvati M; Arcella A; Buttarelli F; D'Elia A; Lanzetta G; Esposito V; Scarpino S; Maurizi Enrici R; Giangaspero F
    J Neurooncol; 2011 Apr; 102(2):311-6. PubMed ID: 20686820
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MGMT promoter methylation status and MGMT and CD133 immunohistochemical expression as prognostic markers in glioblastoma patients treated with temozolomide plus radiotherapy.
    Melguizo C; Prados J; González B; Ortiz R; Concha A; Alvarez PJ; Madeddu R; Perazzoli G; Oliver JA; López R; Rodríguez-Serrano F; Aránega A
    J Transl Med; 2012 Dec; 10():250. PubMed ID: 23245659
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.
    Barbagallo GM; Paratore S; Caltabiano R; Palmucci S; Parra HS; Privitera G; Motta F; Lanzafame S; Scaglione G; Longo A; Albanese V; Certo F
    Neurosurg Focus; 2014 Dec; 37(6):E4. PubMed ID: 25434389
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MGMT gene silencing and benefit from temozolomide in glioblastoma.
    Hegi ME; Diserens AC; Gorlia T; Hamou MF; de Tribolet N; Weller M; Kros JM; Hainfellner JA; Mason W; Mariani L; Bromberg JE; Hau P; Mirimanoff RO; Cairncross JG; Janzer RC; Stupp R
    N Engl J Med; 2005 Mar; 352(10):997-1003. PubMed ID: 15758010
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunohistochemical analysis of O6-methylguanine-DNA methyltransferase (MGMT) protein expression as prognostic marker in glioblastoma patients treated with radiation therapy with concomitant and adjuvant Temozolomide.
    Younis SG; Khedr RA; El-Shorbagy SH
    J Egypt Natl Canc Inst; 2016 Mar; 28(1):23-30. PubMed ID: 26682634
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MGMT gene promoter methylation as a potent prognostic factor in glioblastoma treated with temozolomide-based chemoradiotherapy: a single-institution study.
    Kim YS; Kim SH; Cho J; Kim JW; Chang JH; Kim DS; Lee KS; Suh CO
    Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):661-7. PubMed ID: 22414280
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Temozolomide concomitant and adjuvant to radiotherapy in elderly patients with glioblastoma: correlation with MGMT promoter methylation status.
    Brandes AA; Franceschi E; Tosoni A; Benevento F; Scopece L; Mazzocchi V; Bacci A; Agati R; Calbucci F; Ermani M
    Cancer; 2009 Aug; 115(15):3512-8. PubMed ID: 19514084
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma.
    Donson AM; Addo-Yobo SO; Handler MH; Gore L; Foreman NK
    Pediatr Blood Cancer; 2007 Apr; 48(4):403-7. PubMed ID: 16609952
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A pilot study of glioblastoma multiforme in elderly patients: treatments, O-6-methylguanine-DNA methyltransferase (MGMT) methylation status and survival.
    Abhinav K; Aquilina K; Gbejuade H; La M; Hopkins K; Iyer V
    Clin Neurol Neurosurg; 2013 Aug; 115(8):1375-8. PubMed ID: 23333005
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MGMT promoter methylation status and prognosis of patients with primary or recurrent glioblastoma treated with carmustine wafers.
    Gutenberg A; Bock HC; Brück W; Doerner L; Mehdorn HM; Roggendorf W; Westphal M; Felsberg J; Reifenberger G; Giese A
    Br J Neurosurg; 2013 Dec; 27(6):772-8. PubMed ID: 23662801
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Defining optimal cutoff value of MGMT promoter methylation by ROC analysis for clinical setting in glioblastoma patients.
    Yuan G; Niu L; Zhang Y; Wang X; Ma K; Yin H; Dai J; Zhou W; Pan Y
    J Neurooncol; 2017 May; 133(1):193-201. PubMed ID: 28516344
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Promoter methylation analysis of O6-methylguanine-DNA methyltransferase in glioblastoma: detection by locked nucleic acid based quantitative PCR using an imprinted gene (SNURF) as a reference.
    Morandi L; Franceschi E; de Biase D; Marucci G; Tosoni A; Ermani M; Pession A; Tallini G; Brandes A
    BMC Cancer; 2010 Feb; 10():48. PubMed ID: 20167086
    [TBL] [Abstract][Full Text] [Related]  

  • 17. O-methylguanine-DNA methyltransferase (MGMT) mRNA expression predicts outcome in malignant glioma independent of MGMT promoter methylation.
    Kreth S; Thon N; Eigenbrod S; Lutz J; Ledderose C; Egensperger R; Tonn JC; Kretzschmar HA; Hinske LC; Kreth FW
    PLoS One; 2011 Feb; 6(2):e17156. PubMed ID: 21365007
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MGMT inactivation and clinical response in newly diagnosed GBM patients treated with Gliadel.
    Grossman R; Burger P; Soudry E; Tyler B; Chaichana KL; Weingart J; Olivi A; Gallia GL; Sidransky D; Quiñones-Hinojosa A; Ye X; Brem H
    J Clin Neurosci; 2015 Dec; 22(12):1938-42. PubMed ID: 26249244
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is the absolute value of O(6)-methylguanine-DNA methyltransferase gene messenger RNA a prognostic factor, and does it predict the results of treatment of glioblastoma with temozolomide?
    Tanaka S; Akimoto J; Narita Y; Oka H; Tashiro T
    J Neurosurg; 2014 Oct; 121(4):818-26. PubMed ID: 25105699
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Extent of MGMT promoter methylation correlates with outcome in glioblastomas given temozolomide and radiotherapy.
    Dunn J; Baborie A; Alam F; Joyce K; Moxham M; Sibson R; Crooks D; Husband D; Shenoy A; Brodbelt A; Wong H; Liloglou T; Haylock B; Walker C
    Br J Cancer; 2009 Jul; 101(1):124-31. PubMed ID: 19536096
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.